Clinical Trials Sponsored by Boehringer Ingelheim Pharmaceuticals

Total 2525 results

Boehringer Ingelheim

Completed

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Pain, Postoperative

Italy
Boehringer Ingelheim

Completed

Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

Acute Pain | Dysmenorrhea

Peru
Boehringer Ingelheim

Completed

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Healthy

Germany
Boehringer Ingelheim

Completed

Validation of Predictors of OAC Initiation Using EMR Data

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Healthy Volunteers

China
Boehringer Ingelheim

Completed

Patient Convenience Study

Atrial Fibrillation

Belgium, Denmark, Greece, Netherlands, Norway, Portugal, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Healthy

New Zealand
Boehringer Ingelheim

Completed

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Neoplasms

Belgium
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

Neoplasms

Belgium
Boehringer Ingelheim

Completed

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Non-alcoholic Fatty Liver Disease

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Canada, Belgium, Australia, United Kingdom, Germany, Italy, France, Japan, Mexico, India
Boehringer Ingelheim

Completed

OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)

Pulmonary Disease, Chronic Obstructive

Austria, Czechia, Hungary, Israel, Romania, Russian Federation, Slovakia, Slovenia, Switzerland
Boehringer Ingelheim

Completed

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Carcinoma, Non-Small-Cell Lung

Serbia, Thailand, Poland, Romania, Egypt, Philippines, Malaysia
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

China, Korea, Republic of, Thailand
Boehringer Ingelheim

Completed

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Spain, Korea, Republic of, Thailand, Malaysia, Poland, Russian Federation, Serbia, Bulgaria, Chile, Estonia, Germany, Hungary, Ukraine
Boehringer Ingelheim

Completed

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Alzheimer Disease

United States, Spain, Canada, United Kingdom, Germany, Italy, Netherlands, Portugal, Austria, Belgium, France, Poland
Boehringer Ingelheim

Completed

Anticoagulants Comparative Benefit-risk Ratio in Real Life

Atrial Fibrillation

France
Boehringer Ingelheim

Completed

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 695501

Healthy

Netherlands, Belgium
Boehringer Ingelheim

Completed

Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects

Healthy Volunteers

South Africa
Boehringer Ingelheim

Completed

Fingerprinting of Impulsivity

Impulse Control Disorders

United States
Boehringer Ingelheim

Completed

Long-term Observation PMS for Afatinib

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

Hepatitis C, Chronic

United States, France, Germany, Spain
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

Spain, Belgium, Czechia, France, Croatia, Germany, Austria, New Zealand, Australia, Greece, Hungary, Poland, Russian Federation
Boehringer Ingelheim

Completed

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)

Healthy
Boehringer Ingelheim

Completed

fMRI in Impulsivity

Borderline Personality Disorder | Impulse Control Disorders

United States
Boehringer Ingelheim

Completed

Asthma Biomarker Study

Asthma

United Kingdom
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Boehringer Ingelheim

Completed

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Neoplasms | Leukemia

Germany, France, Italy, Belgium, Czechia
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Healthy

Germany
Boehringer Ingelheim

Completed

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Canada, Turkey
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
Boehringer Ingelheim

Terminated

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, United Kingdom, Netherlands, Ireland, Argentina, Poland, Mexico, Spain, Bulgaria, Chile, Germany, Ukraine, Portugal, Belgium, Canada, Greece, Hungary
Boehringer Ingelheim

Completed

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage

United States, Spain, United Kingdom, Norway, Taiwan, Israel, Belgium, Australia, Sweden, Singapore, Germany, Italy, New Zealand, Austria, Japan, Canada, Czechia, Portugal, Netherlands, Korea, Republic of, France, Poland, Colombia, Hong... and more
Boehringer Ingelheim

Completed

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Hypertension
Boehringer Ingelheim

Completed

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

HIV Infections | Metabolism, Lipids

Netherlands, United Kingdom
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan

3

Subscribe